DNA vaccine shows promise in training immune system to fight breast cancer
NCT ID NCT02204098
First seen Apr 30, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This early-stage trial tests whether a DNA vaccine targeting mammaglobin-A (a protein found on breast cancer cells) is safe and can boost the immune system against cancer. About 27 adults with ER+, HER2- breast cancer will receive the vaccine while undergoing standard hormone therapy or chemotherapy. The goal is to see if the vaccine triggers an immune response without causing serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.